Alkermes (ALKS) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Alkermes (ALKS) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.79% |
| Mar 31, 2026 | -234.69% |
| Dec 31, 2024 | 332.85% |
| Sep 30, 2024 | 87.71% |
| Jun 30, 2024 | -55.52% |
| Mar 31, 2024 | 93.84% |
| Dec 31, 2023 | 9.90% |
| Sep 30, 2023 | -7.77% |
| Jun 30, 2023 | -15.21% |
| Mar 31, 2023 | -141.64% |
| Dec 31, 2022 | 237.11% |
| Sep 30, 2022 | -112.28% |
| Jun 30, 2022 | 16.06% |
| Mar 31, 2022 | -128.62% |
| Dec 31, 2021 | 532.74% |
| Sep 30, 2021 | -1,326.23% |
| Jun 30, 2021 | 110.55% |
| Mar 31, 2021 | 47.43% |
| Dec 31, 2020 | -31,722.39% |
| Sep 30, 2020 | 99.54% |